Global proptech venture capital firm Pi Labs has secured USD90 million for its oversubscribed latest fund, which will back startups revolutionising the real estate world through technology. This is Pi Labs’ third proptech fund and its largest to date.  The fund’s primary focus will be to invest in early stage proptech startups – from pre-seed to series A stage – around the world, with average investments ranging from USD500,000-USD1.5 million per deal, plus follow-on capital. With a USD90 million investment platform and looking to back the next global proptech unicorn, Pi Labs will also deploy capital during later stage rounds

HarbourVest Partners, a global private markets investment specialist, has held the final close of its HIPEP IX Fund at over USD1.6 billion in commitments. The Fund closed above the target size of USD1.25 billion. HIPEP IX provides investors with access to leading private equity managers and investments in Europe and Asia Pacific, the two major private equity markets outside of the United States. The primary programme is complemented by secondary transactions and direct co-investments which are designed to potentially accelerate performance and enhance overall returns. There is an attractive market opportunity in Europe and Asia Pacific, which jointly comprise 63

Kirkland & Ellis has advised Australian private equity firm BGH Capital on the successful closing of its second vintage flagship private equity fund, BGH Capital Fund II, at approximately AUSD3.6 billion, making it the largest-ever private equity vehicle raised for deployment in Australia and New Zealand. The fund was oversubscribed with a broad mix of global institutional investors, including sovereigns, pensions, endowments and fund of funds.  Kirkland also represented BGH Capital in raising its debut fund, BGH Capital Fund I, which was the largest first-time fund raised for Australia and New Zealand at AUD2.6 billion in 2018.

Atlas Venture, an early stage venture capital firm investing in biotech innovation, has closed its thirteenth fund, raising USD450 million in an oversubscribed fundraise. With Fund XIII, Atlas Venture will continue working alongside talented entrepreneurs to create and invest in a new set of biotech companies aimed at delivering impactful medicines to patients. Atlas Venture has been building and investing in innovative biotech startups for more than two decades. Since 2015, Atlas Venture has raised over USD2 billion and has created and/or invested in over 50 biotech companies. In addition to Fund XIII, Atlas is also investing from Opportunity Fund

NatWest Trustee and Depositary Services has been appointed as the depositary for Beechbrook Capital’s latest fund in its UK SME strategy, Beechbrook UK SME Credit III LP. Beechbrook Capital is a specialist direct lender which focuses on investments in small to medium-sized businesses (SMEs) across a range of industries in the UK and Europe. Since its formation in 2008, the debt manager has raised cEUR1bn across seven funds and has invested in 82 companies in the European lower mid-market.   Its latest vehicle, Beechbrook Capital UK SME Credit III LP, provides mainly senior secured loans to non-private equity-backed companies in

Growth capital investor VGC Partners is launching a GBP10m specialist EIS fund that will invest in early-stage businesses working with the next generation of technology and consumers. The fund will focus on businesses at Series A stage in consumer technology, digital media and gaming. The businesses selected will have proven products and markets plus the potential for rapid user or customer adoption and scalability.  VGC Partners manages over £100m of growth capital, and over the last 10 years has established deep networks with industry executives, corporate partners and funds across its target sectors. The firm will leverage its expansive network

PA Capital has held final closes for two of its private equity funds earlier, with its ninth flagship fund, PA Small Company Private Equity Fund IX (Fund IX) closing at USD473 million, above its USD350 million target, and the PA Small Company Co-investment Fund II (Co-invest II) at its USD200 million hard cap. Consistent with PA’s predecessor multi-manager funds, Fund IX invests with an emphasis on the lower end of the middle market, building a diversified portfolio of fund investments, co-investments, and secondary investments. Co-invest II seeks to capitalise on the firm’s co-investment deal flow generated through its deep GP

Pictet has added to its private equity offering with a new vintage of the successful Monte Rosa Co-Investment franchise. With a long history investing in private equity dating back to 1989, Pictet has committed capital to over 200 co-investments to date.   This new strategy is for professional investors seeking to generate long-term capital appreciation. The strategy will target circa 30 co-investments globally alongside well-known General Partners (GPs), providing clients the opportunity to invest in buy-out, growth and venture capital opportunities.

Robert Smith Communications Group (RSC) has launched a new fund private equity fund, Platinum Fund, the first since the company appointed two management executives with experience raising capital and going public to their advisory board. RSC is a premier marketing and business growth consultancy founded in 2002. It will target select investments of USD1 million to USD10 million in companies in North America through its Z Platinum Fund. Fund manager and entrepreneur Robert Smith has over 20 years experience in industries including B2B, marketing, real estate, financial services, tech, and manufacturing.

Piper Sandler Companies has held the final closing of the Piper Heartland Healthcare Crossover Fund USD, with over USD200 million in committed capital. The Fund has already made seven investments deploying approximately USD40 million in capital. The Fund is the first investment vehicle for Piper Heartland Healthcare Capital (Piper Heartland Healthcare), a dedicated healthcare investment platform within Piper Sandler, and will leverage the firm’s leading healthcare investment banking, capital markets and equity research capabilities. The Fund attracted premier investors from across the globe, including institutional investment firms, strategic investors, endowments and family offices. Building on the industry knowledge and capital